SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GenVec - GNVC
GNVC 7.1930.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: mlkr who wrote (16)4/4/2010 5:04:39 PM
From: Gary Mohilner   of 106
 
Many seem ready to write off TNFerade completely, I don't believe that's happening at all. To me TNFerade should be partnered to someone willing to do the necessary trials in a timely way. To get such a partnership after the PACT failure GNVC must be willing to take far less then they could previously have gotten.

The key is proper funding. GNVC could take Esophageal into a small Pivotal Trial that could take 5 to 10 years, but with the backing of a big Pharma, with perhaps 100 to 200 clinical sites worldwide, with the right protocol it could be completed in under 3 years, but not with survival as the endpoint. I believe that a big Pharma running with TNFerade could gain approval by 2013 or 2014 and have it in additional Pivotal trials that would approve it in many other indications within a couple years of the initial approval.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News